Bonn spin-out secures investment in its series A round.

Rigontec, a biopharmaceutical spin-out of Bonn University, has secured €9.45m ($11.9m) in a series A round including High-Tech Gründerfonds, a venture capital fund managed by the German government and backed by corporates.

NRW.Bank, a development bank for North Rhine-Westphalia, Wellington Partners, a venture capital firm, and Boehringer Ingelheim, a venture fund, also joined.

Rigontec, which was spin out of Bonn’s Institute for Clinical Chemistry and Clinical Pharmacology, is working on therapies for cancer and viral diseases. The company is based on research by Gunther Hartmann and Veit Hornung.

News of the investment reached us via our sister publication Global Corporate Venturing.

Annegret de Baey-Diepolder, co-founder and interim chief executive of Rigontec, said: “I am delighted that Rigontec has secured significant funding from experienced life sciences investors to support the development of this exciting new business. We believe that our proprietary technology, based on world-class research, has the potential to create a new generation of immunotherapies for the treatment of cancer and viral diseases.”